Epoetin beta subcutaneous administration to lung cancer patients with anemia; results of pharmacokinetics/pharmacodynamics study

Japanese Journal of Lung Cancer

Volumn 47, Issue 4, 2007, Pages 313-322

  Nakagawa, Kazuhiko ^a   Ozaki, Tomohiro ^a   Satoh, Taroh ^a   Miyazaki, Masaki ^a   Akashi, Yusaku ^a   Terashima, Masaaki ^a   Fujisaka, Yasuhito ^b   Tamura, Tomohide ^b   Fukuoka, Masahiro ^a   Saijo, Nagahiro ^c  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Anemia; Epoetin beta; Lung cancer; Pharmacodynamics; Pharmacokinetics

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG CANCER; THROMBOCYTE COUNT;

EID: 35148852745     PISSN: 03869628     EISSN: None     Source Type: Journal    
DOI: 10.2482/haigan.47.313     Document Type: Article

References (15)

1. Japanese source
2. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002:87:1209-1221.
3. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
4. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
5. Bokemeyer C, Aapro MS, Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004:40:2201-2216.
6. Morishima Y, Ogura M, Yoneda S, et al. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study. Jpn J Clin Oncol. 2006;36:655-661.
7. Japanese source
8. Beckman DL, Lin LL. Quinones ME, et al. Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin. Blood. 1999;94:2667-2675.
9. Kato M, Kamiyama H, Okazaki A, et al. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther. 1997;283:520-527.
10. Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001;298:820-824.
11. Fujisaka Y, Tamura T, Ohe Y, et al. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Jpn J Clin Oncol. 2006;36:477-482.
12. Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004;93: 2184-2204.
13. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol. 2002;69:265-274.
14. Sawabe Y, Takiguchi Y, Kikuno K, et al. Changes in levels of serum erythropoietin, serum iron and unsaturated iron binding capacity during chemotherapy for lung cancer. Jpn J Clin Oncol. 1998;28:182-186.
15. Piroso E, Erslev AJ, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol. 1989;32:248-254.